Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 345 results for "Ibrutinib"

BRIEF-Janssens Imbruvica receives CHMP opinion for use in lymp...

April 29 Johnson & Johnson * Janssen's Imbruvica (ibrutinib) receives positive CHMP opinion for expanded use in previously untreated chronic lymphocytic leukaemia patients * Positive opinion of CHMP was based on data from phase 3, ... Reuters UK, 3 days ago
Cancer Therapy Advisor

Ibrutinib for Chronic Lymphocytic Leukemia

 New England Journal of Medicine1 week ago Study Assesses Mechanisms Behind Ibrutinib Resistance in CLL  Cancer Therapy Advisor1 week ago Ibrutinib increased survival more than chlorambucil in older patients with untreated chronic lymphocytic leukemia  Annals of Internal Medicine1 week ago A Case of Hypophosphatemiawith Increased Urinary Excretion of Phosphorus Associated with Ibrutinib  Case Reports in Oncology2 weeks ago

European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients

/PRNewswire/ -- AbbVie (NYSE:ABBV), a global biopharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion in favor of the use of ...
 Nasdaq3 days ago 4/29/16 - European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients  Pharmacy Choice3 days ago AbbVie Release: European Medicines Agency Issues Positive Opinion For The Use Of IMBRUVICA (Ibrutinib) As A First-Line Treatment For Chronic Lymphocytic Leukemia Patients  BioSpace3 days ago Human medicines European public assessment report (EPAR): Imbruvica, ibrutinib, Revision: 5, Authorised  European Medicines Agency1 week ago

Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology

-Studies demonstrate potential mechanistic synergies with the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, as well as with immunomodulation- BOSTON--(EON: Enhanced Online News Overall these data further support the broad versatility and ...
 EON: Enhanced Online News1 week ago Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology  BioSpace1 week ago

Ibrutinib in Follicular Lymphoma: Dr Nathan Fowler at ASH 2015

Click here to receive lymphoma news via e-mail [embedded content] In thisLymphoma Hub video, watchDr Nathan Fowler talk about ibrutinib in follicular lymphoma at last year's American Society of Hematology Annual Meeting. Learnmore about ...
 LymphomaNewsToday.com6 days ago 77 Non-Hodgkin's Lymphoma Drugs  LymphomaNewsToday.com3 hours ago

Ibrutinib: Indication of added benefit in one of three therapeutic indications

EurekAlert! provides embargoed and breaking science news you can't afford to miss. EurekAlert! offers a one-stop science news distribution service you can trust. EurekAlert! is a service of the American Association for the Advancement of Science. ...
 EurekAlert!7 hours ago

Ibrutinib Plus Bendamustine and Rituximab Yields Positive Results for Patients With CLL/SLL

Adding ibrutinib to a standard treatment regimen of bendamustine and rituximab for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) led to significant improvements in progression-free survival ...
 ASH Clinical News4 days ago FDA Approves Imbruvica (Ibrutinib for CLL)  Oncology Times4 weeks ago 3/21/16 - IMBRUVICA® ibrutinib Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia  Pharmacy Choice1 month ago U.S. FDA Approves IMBRUVICA ibrutinib for First-line Treatment of Chronic Lymphocytic Leukemia  Pharmacy Choice1 month ago

Ibrutinib and Waldenstroms Macroglobulin...

Description: Morie A. Gertz, MD of Mayo Clinic discusses Ibrutinib and Waldenstroms Macroglobulinemia at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in
 Oncology Tube1 week ago How to decide between Ibrutinib and Idel...  Oncology Tube2 weeks ago Ibrutinib or Idelalisib Selecting Approp...  Oncology Tube1 month ago

Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL

[embedded content] Jeffrey Jones, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL) who progress on, or become ...
 Targeted Oncology2 weeks ago

Ibrutinib Disrupts CLL Tumor-Microenvironment Interactions

1 , 2 , Sarah E.M. Herman 1 , Irina Maric 3 , Julio Gomez-Rodriguez 4 , Angelique Biancotto 5 , Betty Y. Chang 6 , Sabrina Martyr 1 , Maryalice Stetler-Stevenson 7 , Constance M. Yuan 7 , Katherine R. Calvo 3 , Raul C. Braylan 3 , Janet ...
 Clinical Cancer Research1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Ibrutinib
Get updated on latest news & your favorite topics right in your inbox!
More     Less